Cargando…

Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells

PURPOSE: MYC-driven Group 3 medulloblastoma (MB) (subtype II) is a highly aggressive childhood brain tumor. Sensitivity of MYC-driven MB to class I histone deacetylase inhibitors (HDACi) has been previously demonstrated in vitro and in vivo. In this study we characterize the transcriptional effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vollmer, Johanna, Ecker, Jonas, Hielscher, Thomas, Valinciute, Gintvile, Ridinger, Johannes, Jamaladdin, Nora, Peterziel, Heike, van Tilburg, Cornelis M., Oehme, Ina, Witt, Olaf, Milde, Till
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589189/ https://www.ncbi.nlm.nih.gov/pubmed/37783879 http://dx.doi.org/10.1007/s11060-023-04445-w

Ejemplares similares

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

Targeting protein folding in N‐Myc‐driven medulloblastoma
por: Valinciute, Gintvile, et al.
Publicado: (2023)

Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts
por: Wrobel, Jagoda K, et al.
Publicado: (2020)

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
por: Müller, Michael, et al.
Publicado: (2021)

Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma
por: Körholz, Katharina, et al.
Publicado: (2021)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance
por: Ridinger, Johannes, et al.
Publicado: (2018)

Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance
por: Bingel, Corinna, et al.
Publicado: (2017)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein
por: Rösch, Lisa, et al.
Publicado: (2022)

MODL-01. Targeting replication stress in pediatric brain tumors
por: Krausert, Sonja, et al.
Publicado: (2022)

MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation
por: Kolodziejczak, Anna, et al.
Publicado: (2022)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
por: Koeneke, Emily, et al.
Publicado: (2015)

Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma
por: Krausert, Sonja, et al.
Publicado: (2022)

Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors
por: Morgen, Michael, et al.
Publicado: (2020)

The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines
por: Kolbinger, Fiona R., et al.
Publicado: (2018)

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment
por: Shen, Jing, et al.
Publicado: (2018)

MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2013)

Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma
por: Schwinn, Stefanie, et al.
Publicado: (2021)

BIOL-10. DISTRIBUTION AND VULNERABILITY OF TRANSCRIPTIONAL OUTPUTS ACROSS THE GENOME IN MYC-AMPLIFIED MEDULLOBLASTOMA CELLS
por: Yang, Rui, et al.
Publicado: (2021)

LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma
por: Kocher, Daniela, et al.
Publicado: (2022)

Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma
por: Bharambe, Harish Shrikrishna, et al.
Publicado: (2020)

Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1
por: Zhao, Yang, et al.
Publicado: (2020)

MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
por: Kameda-Smith, Michelle, et al.
Publicado: (2020)

Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
por: Wang, Jiajia, et al.
Publicado: (2020)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
por: Kling, Matthew J., et al.
Publicado: (2022)

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing
por: Selt, Florian, et al.
Publicado: (2016)

Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models
por: Gatzweiler, Charlotte, et al.
Publicado: (2022)

LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA
por: Selt, Florian, et al.
Publicado: (2021)

LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics
por: Sigaud, Romain, et al.
Publicado: (2022)

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR
por: Stepien, Natalia, et al.
Publicado: (2023)

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma
por: Adiamah, Magretta, et al.
Publicado: (2022)

LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY
por: Usta, Diren, et al.
Publicado: (2020)

EMBR-02. OLIG2 REPRESENTS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-AMPLIFIED MEDULLOBLASTOMA RELAPSE AND METASTASIS
por: Xu, Zhenhua, et al.
Publicado: (2021)

MBRS-62. CURAXIN CBL0137 INHIBITS THE VIABILITY OF CANCEROUS CELLS IN PRE-CLINIC MODELS OF MYC-AMPLIFIED MEDULLOBLASTOMA
por: Wang, Jiajia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_smkpk5kval0srs1fhgp451ijfo